Clinical Trial Detail

NCT ID NCT02432963
Title Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center
Indications

head and neck squamous cell carcinoma

triple-receptor negative breast cancer

renal cell carcinoma

pancreatic cancer

hepatocellular carcinoma

sarcoma

Advanced Solid Tumor

colorectal cancer

bladder carcinoma

ovarian cancer

lung non-small cell carcinoma

melanoma

Therapies

MVAp53 + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.